Ancilia Biosciences is focused on leveraging the natural capabilities of CRISPR technology to address challenges posed by the virome, which consists of the vast array of viruses that interact with beneficial bacteria. Their approach includes the development of two key platforms: CoVE™ (Computational Virome Engine) and EPIC™ (Enhancing Phage Immunity with CRISPR). The CoVE™ platform is designed to identify and characterize the diverse and complex nature of viruses, enabling the creation of targeted solutions to mitigate their harmful effects. Meanwhile, the EPIC™ platform utilizes CRISPR's inherent immune functions to enhance the resilience of beneficial bacteria against viral threats, thereby improving their therapeutic potential.

By harnessing these advanced technologies, Ancilia aims to create innovative live biotherapeutics and other bacterial products that can effectively combat viral infections. Their mission is to unlock the full therapeutic potential of beneficial bacteria by ensuring they are equipped with immunity against destructive viruses, ultimately contributing to advancements in healthcare, agriculture, and industrial biotechnology. Through their proprietary CRISPR tools and platforms, Ancilia is positioned to make significant strides in the understanding and application of virome-related solutions.

United States

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

Ancilia Biosciences

Company Details